000 01552 a2200445 4500
005 20250515084146.0
264 0 _c20071127
008 200711s 0 0 eng d
022 _a1464-4096
024 7 _a10.1111/j.1464-410X.2007.07095.x
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aAlbouy, Baptiste
245 0 0 _aPreliminary results of the Prostacox phase II trial in hormonal refractory prostate cancer.
_h[electronic resource]
260 _bBJU international
_cOct 2007
300 _a770-4 p.
_bdigital
500 _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
650 0 4 _aAged
650 0 4 _aAged, 80 and over
650 0 4 _aAntineoplastic Combined Chemotherapy Protocols
_xadverse effects
650 0 4 _aCelecoxib
650 0 4 _aDocetaxel
650 0 4 _aHumans
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aProstate-Specific Antigen
_xblood
650 0 4 _aProstatic Neoplasms
_xblood
650 0 4 _aPyrazoles
_xadministration & dosage
650 0 4 _aQuality of Life
650 0 4 _aSulfonamides
_xadministration & dosage
650 0 4 _aTaxoids
_xadministration & dosage
650 0 4 _aTreatment Outcome
700 1 _aTourani, Jean-Marc
700 1 _aAllain, Patrick
700 1 _aRolland, Frederic
700 1 _aStaerman, Frederic
700 1 _aEschwege, Pascal
700 1 _aPfister, Christian
773 0 _tBJU international
_gvol. 100
_gno. 4
_gp. 770-4
856 4 0 _uhttps://doi.org/10.1111/j.1464-410X.2007.07095.x
_zAvailable from publisher's website
999 _c17350938
_d17350938